睿知中国医院研究地图
候选清单

正在招募胃肠道间质瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of Olverembatinib in SDH-deficient GIST.

ClinicalTrials.gov 上登记的一项胃肠道间质瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06640361,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 12 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Negative serum pregnancy test result for women of childbearing potential within 7 days prior to taking the first dose of study drug.

    入选标准第 6 条

    Males, women of childbearing potential, as well as their partners, voluntarily take effective contraceptive measures as specified in the protocol from the time of signing the informed consent form until at least 30 days after the last dose of study drug.

    入选标准第 7 条

    Received antitumor cytotoxic chemotherapy, radiotherapy, biologic drug therapy, immunotherapy, or other investigational agents within 14 days or less than 5 times the half-life prior to the first dose.

    排除标准第 1 条

    Adverse events due to prior treatment have not recovered (> NCI CTCAE v5.0 Grade 1).

    排除标准第 4 条

    Major surgery, open biopsy, or major traumatic injury within 14 days prior to initiation of study drug.

    排除标准第 10 条

  3. ECOG≤ 2.

    入选标准第 3 条

  4. Other malignancies within 2 years.

    排除标准第 12 条

  5. Female patients who are pregnant or lactating, or female patients who are expecting to become pregnant within the period of this study.

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06640361,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Histologically and/or cytologically confirmed GIST, immunohistochemistry with loss of SDHB expression, and failure of at least one prior systemic therapy. Defined as disease progression or intolerable as judged by the investigator.
  2. Must have at least one measurable target lesion.
  3. ECOG≤ 2.
  4. Expected survival of at least 3 months.
  5. Adequate organ function.
  6. Negative serum pregnancy test result for women of childbearing potential within 7 days prior to taking the first dose of study drug.
  7. Males, women of childbearing potential, as well as their partners, voluntarily take effective contraceptive measures as specified in the protocol from the time of signing the informed consent form until at least 30 days after the last dose of study drug.
  8. Prior to initiation of any screening or study-specific procedures, the patient or his/her guardian is able to understand and voluntarily sign an informed consent form approved by the Ethics Committee in writing, voluntarily and able to complete the study procedures and follow-up examinations.

排除标准:Exclusion Criteria:

  1. Received antitumor cytotoxic chemotherapy, radiotherapy, biologic drug therapy, immunotherapy, or other investigational agents within 14 days or less than 5 times the half-life prior to the first dose.
  2. Tyrosine kinase inhibitor (TKI) therapy within 7 days prior to the first dose.
  3. Use of drugs that have drug interactions with the study drug within 7 days prior to the first dose.
  4. Adverse events due to prior treatment have not recovered (> NCI CTCAE v5.0 Grade 1).
  5. Absorption disorder syndrome or other conditions that affect the absorption of oral medications.
  6. With clinically significant, uncontrolled or active cardiovascular disease or thrombotic disease.
  7. Poorly controlled hypertension after hypertension medication.
  8. Severe cardiovascular and cerebrovascular diseases during previous use of TKIs.
  9. Uncontrolled Hyperlipidemia.
  10. Major surgery, open biopsy, or major traumatic injury within 14 days prior to initiation of study drug.
  11. With brain metastases.
  12. Other malignancies within 2 years.
  13. Uncontrolled systemic active fungal, bacterial, and/or viral infections.
  14. Female patients who are pregnant or lactating, or female patients who are expecting to become pregnant within the period of this study.
  15. Any symptoms or disease of the patient, in the judgment of the investigator or sponsor, that may jeopardize their safety or interfere with the safety evaluation of the investigational drug.

引自 ClinicalTrials.gov, NCT06640361, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06640361,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06640361